Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Angiogenesis Inhibitors: Helping or Hurting?

    Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse? This unnerving thought comes courtesy of two recent studies on VEGF pathway inhibitors which present what… Read More
  • Cancer

    Into the Clinic. And Right Back Out.

    Here’s a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies. A company called SGX, recently acquired by Eli Lilly, has been developing a kinase inhibitor (SGX523) targeting the enzyme cMET. That’s a well-known anticancer drug target, with a lot of activity going on in the… Read More
  • Business and Markets

    Dendreon’s Stock: What the Hey?

    We now have more data on Dendreon’s results for their prostate cancer therapy Provenge, and the numbers do, in fact, look good. This isn’t a cure for refractory prostate cancer, but there seems to be a real statistical improvement in survival, with side effects no worse than the placebo group, and that should be enough… Read More
  • Business and Markets

    Dendreon’s Revenge?

    Post updated below – DBL Dendreon is a company that’s really been through it, as have their investors. Many will remember the upheaval back in 2007, when the company showed what they felt were impressive results for their autologous prostate cancer immunotherapy Provenge, got a favorable reception from the FDA’s advisory panel, bu… Read More
  • Biological News

    The Motions of a Protein

    So, people like me spend their time trying to make small molecules that will bind to some target protein. So what happens, anyway, when a small molecule binds to a target protein? Right, right, it interacts with some site on the thing, hydrogen bonds, hydrophobic interactions, all that – but what really happens? That’s surprisingly… Read More
  • Cancer

    Kinases: Hot or Not?

    For the last ten or fifteen years, untold amounts of time and money have been spent developing drugs to inhibit kinase enzymes. Just go take a look at KinasePro’s archives; that’ll give you the idea. Huge programs have been run at all the major drug companies, and any number of smaller ones have been founded… Read More
  • Cancer

    Curse Of the Lost Compounds

    There are some groups of compounds that seem to have a curse on them. They show up in drug screening, they have activity that’s often too good to ignore, but hardly anyone can manage to turn one of them into a drug. Trifluoromethyl ketones are one example of this. They’re classic inhibitors of proteases, especially… Read More
  • Cancer

    Sunesis: No Substitutions Allowed?

    A colleague mentioned to me the other day that Sunesis Pharmaceuticals had let many of its remaining research staff go back during the summer – they’re battening down to try to get their main clinical candidate through for leukemia and ovarian cancer. That’s a common phase of life for a small company trying to go… Read More
  • Business and Markets

    BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra

    I haven’t mentioned the attempt by Bristol-Meyers Squibb to buy out Imclone until now, but there’s a nice . The reasons for the move are unsurprising – BMS would like all the revenue from Erbitux, instead of just a share of it, and sees some value coming up in Imclone’s pipeline (such as their development… Read More
  • Cancer

    The Complicated Causes of Cancer

    Since I was just banging on the table (or the lab bench) the other day about how many diseases aren’t single-factor, and about how many diseases (like cancer) aren’t even single diseases, I thought this would be a good time to haul out some evidence for that. The data are here thanks to some recent… Read More